Neglected hepatitis D / 中华检验医学杂志

ABSTRACT

Hepatitis D virus (HDV) is a defective virus that requires hepatitis B surface antigen (HBsAg) to replicate. HDV infection is prevalent worldwide, but the number of HDV infections varies in different regions of the world, and there is no exact global prevalence data for hepatitis D. China belongs to an area with low prevalence of anti-HDV. However, the positive rates of anti-HDV are relatively high in Inner Mongolia Autonomous Region and Xinjiang Uygur Autonomous Region. compared to HBV monoinfection chronic HBV/HDV coinfection progresses more rapidly and frequently to cirrhosis,liver decompensation and hepatocellular carcinoma. Anti-HBV nucleotide analogues (NAs) that inhibit HBV replication are ineffective in controlling HDV infection. The newly approved drug Burweipeptide (BLV) has demonstrated good safety and efficacy in the treatment of chronic hepatitis D, and no drug-resistant mutations have been found so far.